{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333827","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-08-05T11:08:16+00:00","discovered_at":"2026-08-05T11:10:00.421066+00:00","generated_at":"2026-08-05T11:10:07.506314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NewAmsterdam reports Q2 net loss of $64.1M; CHMP recommends EU approval for obicetrapib","bullets":["CHMP positive opinion for obicetrapib monotherapy and FDC with ezetimibe; EC decision expected later 2026.","Cash, cash equivalents and marketable securities $678.3M at June 30, 2026, down from $728.9M at Dec 31, 2025.","Net loss $64.1M in Q2 2026 vs $17.4M in Q2 2025; revenue $3.7M vs $19.1M (prior year included $16.1M Menarini milestone).","PREVAIL CVOT interim analysis planned for 4Q2026, result in 1Q2027; RUBENS Phase 3 topline data expected by year-end 2026.","R&D expenses $41.7M (up from $27.5M) driven by clinical trial progression; SG&A $26.9M (down from $27.3M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333827","json":"https://secwatch.observer/filing/0001193125-26-333827.json","markdown":"https://secwatch.observer/filing/0001193125-26-333827.md","text":"https://secwatch.observer/filing/0001193125-26-333827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/0001193125-26-333827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:10:07.506314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}